Vildagliptin restores renal myogenic function and attenuates renal sclerosis independently of effects on blood glucose or proteinuria in Zucker diabetic fatty rat

Current Vascular Pharmacology

Volumn 12, Issue 6, 2014, Pages 836-844

  Vavrinec, Peter ^a,b   Henning, Robert H ^a,b   Landheer, Sjoerd W ^a,b   Wang, Yumei ^a,b   Deelman, Leo E ^a,b   van Dokkum, Richard P E ^a,b   Buikema, Hendrik ^a,b  

^a Physics and Informatics   (Slovakia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic kidney disease; DPP IV inhibitors; Glomerulosclerosis; Glucagon like peptide 1; Myogenic constriction; Oxidative stress; Type 2 diabetes melitus; ZDF rat

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; MESSENGER RNA; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIOGRAPHY; ARTICLE; BLOOD VESSEL REACTIVITY; CHRONIC KIDNEY DISEASE; FOCAL GLOMERULOSCLEROSIS; GENE; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY FIBROSIS; MALE; MESENTERIC ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; P22PHOX GENE; PROTEIN EXPRESSION; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL ARTERY; RENAL SCLEROSIS; ZUCKER DIABETIC FATTY RAT;

EID: 84926297509     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/15701611113116660151     Document Type: Article

References (57)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-55.
2. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998; 6: 97-106.
3. Fulop T, Tessier D, Carpentier A. The metabolic syndrome. Pathol Biol (Paris) 2006; 54: 375-86.
4. Johansen OE, Birkeland KI. Preventing macrovascular disease in patients with type 2 diabetes mellitus. Am J Cardiovasc Drugs 2003; 3: 283-97.
5. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-68.
6. Stengel B, Tarver-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479-87.
7. Locatelli F, Pozzoni P, Del VL. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 2006; 17: S81-5.
8. Newsholme P, Homem De Bittencourt PI, O' HC, De VG, Murphy C, Krause MS. Exercise and possible molecular mechanisms of protection from vascular disease and diabetes: the central role of ROS and nitric oxide. Clin Sci 2010; 118: 341-9.
9. Hill MA, Davis MJ, Meininger GA, Potocnik SJ, Murphy TV. Arteriolar myogenic signalling mechanisms: Implications for local vascular function. Clin Hemorheol Microcirc 2006; 34: 67-79.
10. Murphy TV, Spurrell BE, Hill MA. Cellular signalling in arteriolar myogenic constriction: involvement of tyrosine phosphorylation pathways. Clin Exp Pharmacol Physiol 2002; 29: 612-9.
11. Davis MJ, Wu X, Nurkiewicz TR, et al. Integrins and mechanotransduction of the vascular myogenic response. Am J Physiol 2001; 280: H1427-33.
12. Hill MA, Meininger GA, Davis MJ, Laher I. Therapeutic potential of pharmacologically targeting arteriolar myogenic tone. Trends Pharmacol Sci 2009; 30: 363-74.
13. Kotecha N, Hill MA. Myogenic contraction in rat skeletal muscle arterioles: smooth muscle membrane potential and Ca(2+) signaling. Am J Physiol 2005; 289: H1326-34.
14. Davis MJ, Hill MA. Signaling mechanisms underlying the vascular myogenic response. Physiol Rev 1999; 79: 387-423.
15. Takenaka T, Suzuki H, Okada H, Hayashi K, Ozawa Y, Saruta T. Biophysical signals underlying myogenic responses in rat interlobular artery. Hypertension 1998; 32: 1060-5.
16. Bai N, Moien-Afshari F, Washio H, Min A, Laher I. Pharmacology of the mouse-isolated cerebral artery. Vasc Pharmacol 2004; 41: 97-106.
17. Simons JL, Provoost AP, Anderson S, et al. Pathogenesis of glomerular injury in the fawn-hooded rat: early glomerular capillary hypertension predicts glomerular sclerosis. J Am Soc Nephrol 1993; 3: 1775-82.
18. Simons JL, Provoost AP, De Keijzer MH, Anderson S, Rennke HG, Brenner BM. Pathogenesis of glomerular injury in the fawnhooded rat: effect of unilateral nephrectomy. J Am Soc Nephrol 1993; 4: 1362-70.
19. Daneshtalab N, Smeda JS. Alterations in the modulation of cerebrovascular tone and blood flow by nitric oxide synthases in SHRsp with stroke. Cardiovasc Res 2010; 86: 160-8.
20. Hayashi K, Epstein M, Loutzenhiser R, Forster H. Impaired myogenic responsiveness of the afferent arteriole in streptozotocininduced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992; 2: 1578-86.
21. Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol Med 1983; 173: 68-75.
22. Sparks JD, Shaw WN, Corsetti JP, Bolognino M, Pesek JF, Sparks CE. Insulin-treated Zucker diabetic fatty rats retain the hypertriglyceridemia associated with obesity. Metabolism 2000; 49: 1424-30.
23. Ban K, Hui S, Drucker DJ, Husain M. Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin-based therapies. J Am Soc Hypertens 2009; 3: 245-59.
24. Gschwend S, Buikema H, Navis G, Henning RH, de Zeeuw D, Van Dokkum RP. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat. J Am Soc Nephrol 2002; 13: 2909-15.
25. Smit-van OA, Navis G, Stegeman CA, et al. Chronic blockade of angiotensin II action prevents glomerulosclerosis, but induces graft vasculopathy in experimental kidney transplantation. J Pathol 2001; 194: 122-9.
26. Rook M, Lely AT, Kramer AB, van GH, Navis G. Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage. Nephrol Dial Transplant 2005; 20: 59-64.
27. Sandovici M, Henning RH, van GH, Helfrich W, de ZD, Deelman LE. Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Kidney Int 2008; 73: 1364-73.
28. Vavrincova-Yaghi D, Deelman LE, Goor H, et al. Gene therapy with adenovirus-delivered indoleamine 2,3-dioxygenase improves renal function and morphology following allogeneic kidney transplantation in rat. J Gene Med 2011; 13: 373-81.
29. Takenaka T, Inoue T, Ohno Y, et al. Elucidating mechanisms underlying altered renal autoregulation in diabetes. Am J Physiol Physiol 2012; 303: R495-504.
30. Takenaka T, Inoue T, Okada H, et al. Altered gap junctional communication and renal haemodynamics in Zucker fatty rat model of type 2 diabetes. Diabetologia 2011; 54: 2192-201.
31. Jerums G, Premaratne E, Panagiotopoulos S, Macisaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia 2010; 53: 2093-104.
32. Hayashi K, Epstein M, Loutzenhiser R, Forster H. Impaired myogenic responsiveness of the afferent arteriole in streptozotocininduced diabetic rats: role of eicosanoid derangements. J Am Soc Nephrol 1992; 2: 1578-86.
33. Schofield I, Malik R, Izzard A, Austin C, Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002; 106: 3037-43.
34. Chander PN, Gealekman O, Brodsky SV, et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 2004; 15: 2391-403.
35. Mizuno M, Sada T, Kato M, Fukushima Y, Terashima H, Koike H. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes. J Cardiovasc Pharmacol 2006; 48: 135-42.
36. Maneen MJ, Hannah R, Vitullo L, DeLance N, Cipolla MJ. Peroxynitrite diminishes myogenic activity and is associated with decreased vascular smooth muscle F-actin in rat posterior cerebral arteries. Stroke 2006; 37: 894-9.
37. Zagorac D, Yamaura K, Zhang C, Roman RJ, Harder DR. The effect of superoxide anion on autoregulation of cerebral blood flow. Stroke 2005; 36: 2589-94.
38. Ge Y, Murphy SR, Lu Y, Falck J, Liu R, Roman RJ. Endogenously produced 20-HETE modulates myogenic and TGF response in microperfused afferent arterioles. Prostaglandins Other Lipid Mediat 2013; 102-3: 42-8.
39. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen speciesregulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003; 14: S241-5.
40. Daull P, Blouin A, Beaudoin M, et al. The hemodynamic and metabolic profiles of Zucker diabetic fatty rats treated with a single molecule triple vasopeptidase inhibitor, CGS 35601. Exp Biol Med 2006; 231: 824-9.
41. Fredersdorf S, Thumann C, Ulucan C, et al. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol 2004; 13: 11-9.
42. Ferreira L, Teixeira-de-Lemos E, Pinto F, et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010; 2010: 59 2760.
43. Ito I, Jarajapu YP, Guberski DL, Grant MB, Knot HJ. Myogenic tone and reactivity of rat ophthalmic artery in acute exposure to high glucose and in a type II diabetic model. Invest Ophthalmol Vis Sci 2006; 47: 683-92.
44. Burkey BF, Li X, Bolognese L, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005; 315: 688-95.
45. Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-yl methyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009; 328: 556-63.
46. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol Cell Endocrinol 1998; 141: 179-86.
47. Korner M, Stockli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48: 736-43.
48. Oeseburg H, de Boer RA, Buikema H, van der HP, van Gilst WH, Sillje HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010; 30: 1407-14.
49. Kim JY, Lim DM, Moon CI, et al. Exendin-4 protects oxidative stress-induced beta-cell apoptosis through reduced JNK and GSK3beta activity. J Korean Med Sci 2010; 25: 1626-32.
50. Mukai E, Fujimoto S, Sato H, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 2011; 60: 218-26.
51. Goto H, Nomiyama T, Mita T, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011; 405: 79-84.
52. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008; 117: 2340-50.
53. Green BD, Hand KV, Dougan JE, McDonnell BM, Cassidy RS, Grieve DJ. GLP-1 and related peptides cause concentrationdependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys 2008; 478: 136-42.
54. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-6.
55. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemiareperfusion injury in rat heart. Regul Pept 2008; 146: 243-9.
56. Yu M, Moreno C, Hoagland KM, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-35.
57. Singh A, Friden V, Dasgupta I, et al. High glucose causes dysfunction of the human glomerular endothelial glycocalyx. Am J Physiol Renal Physiol 2011; 300: F40-8.